|
Cardiomyopathy, Dilated
|
0.200 |
Biomarker
|
group |
MGD |
|
|
|
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In the present study, we first demonstrated that Rab1A was overexpressed in CRC tissues and Rab1A overexpression was positively related to lymph node invasion, degree of differentiation, venous invasion and tumor‑node‑metastasis (TNM) stage.
|
30896866 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Expression analysis and implication of Rab1A in gastrointestinal relevant tumor.
|
31527621 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, these data suggest that miR‑139‑3p plays a tumor suppressive role in breast cancer by targeting RAB1A and may serve as a potential new biomarker for breast cancer prognosis.
|
31485677 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High expression of Rab1A was closely related to the tumor size and the depth of tumor invasion.
|
31038077 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Final pathologic tumor category (AJCC eighth edition) was 46.9% ypT1, 34.4% ypT2, and 18.7% ypT3.
|
30211728 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Rab1a, a member RAS oncogene family, has been reported playing important role in tumor proliferation and migration.
|
29672195 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The results demonstrated that Rab1A was significantly overexpressed in the different histological types of lung cancer as compared to non-cancerous tissues, and Rab1A expression was correlated with tumor volume and stage.
|
27902464 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, our data suggest that miR-15b-5p induces ERS, apoptosis, and growth inhibition by targeting and suppressing Rab1A, acting as a tumor suppressor gene in HCC.
|
26023735 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, the oral administration of KPS-A led to substantial inhibition of tumor growth and the expression of proliferating cell nuclear antigen (PCNA), MMP-9, tissue inhibitor of metalloproteinase-1 (TIMP-1), HuR, and Rab1A in the tumor tissues of mice inoculated with YD-10B OSCC cells.
|
22382313 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, the fact that the expression of ADS31/YPT1 transcript becomes dominant in the advanced stages of androgen-independent growth, suggests that the mechanism of progression is subserved by duplication and possibly redundancy of alternative (signal transduction) pathways mediating tumour cell survival and growth.
|
8049130 |
1994 |
|
Colorectal Carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry and western blot were conducted to determine the RAB1A expression in CRC tissues and cells, respectively.
|
31598673 |
2020 |
|
Colorectal Carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
The level of p‑S6K1 was markedly high in CRC tissues and Rab1A expression level had a positive association with p‑S6K1 level.
|
30896866 |
2019 |
|
Colorectal Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Previous studies have reported an oncogenic function of Rab1A in colorectal cancer and hepatocellular carcinomas via the mTOR pathway.
|
31527621 |
2019 |
|
Colorectal Carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Moreover, Kaplan-Meier survival analysis showed that patients with high Rab1A expression had a significantly worse survival time than those with low Rab1A expression, which especially affected the survival in CRC patients with advanced stage.
|
30058685 |
2018 |
|
Colorectal Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
RAB1A acts as an oncogene in various cancers, and emerging evidence has verified that RAB1A is an mTORC1 activator in hepatocellular and colorectal cancer, but the role of RAB1A in breast cancer remains unclear.
|
28184936 |
2017 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Taken together, MNX1-AS1 functions as a sponge to miR-218-5p to modulate RAB1A expression in bladder cancer, which suggests that MNX1-AS1 might serve as a novel therapeutic target and a novel biomarker for metastasis and prognosis in bladder cancer.
|
31843814 |
2020 |
|
Neoplasm Metastasis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Collectively, this study suggested that circ_0000218 up-regulated RAB1A and promoted CRC proliferation and metastasis via sponging miR-139-3p.
|
31598673 |
2020 |
|
Malignant Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
We detected significantly higher expression of Rab1A in the gastrointestinal tumor tissues compared to that in other cancer types following an in silico analysis of TGCA and GTEX databases.
|
31527621 |
2019 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Thus, our findings indicate that Rab1A plays an important role in CRC and may provide a therapeutic target for CRC, particularly for mTORC1‑targeted therapy‑resistant cancers.
|
30896866 |
2019 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Patients with rectal cancer staged ypT4N0 were associated with higher locoregional recurrence and distant metastasis rates than those staged ypT1-2N1 in the current staging system.
|
30595556 |
2019 |
|
Liver carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Previous studies have reported an oncogenic function of Rab1A in colorectal cancer and hepatocellular carcinomas via the mTOR pathway.
|
31527621 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
0.040 |
Biomarker
|
disease |
BEFREE |
Previous studies have reported an oncogenic function of Rab1A in colorectal cancer and hepatocellular carcinomas via the mTOR pathway.
|
31527621 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
0.040 |
Biomarker
|
disease |
BEFREE |
Rab1A promotes proliferation and migration abilities via regulation of the HER2/AKT-independent mTOR/S6K1 pathway in colorectal cancer.
|
30896866 |
2019 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Emerging evidence has verified that Rab1A plays an oncogenic role in several human malignancies including breast cancer, lung cancer, and hepatocellular carcinomas.
|
30058685 |
2018 |